Abstract
The c.1529C >T change in the SPG7 gene, encoding the mutant p.Ala510Val paraplegin protein, was first described as a polymorphism in 1998. This was based on its frequency of 3 % and 4 % in two separate surveys of controls in the United Kingdom (UK) population. Subsequently, it has been found to co-segregate with disease in a number of different populations. Yeast expression studies support its having a deleterious effect. In this paper a consanguineous sibship is described in which four members who are homozygous for the p.Ala510Val variant present with a spectrum of disease. This spectrum encompasses moderately severe hereditary spastic paraparesis (HSP) with more minor ataxia in two siblings, moderately severe ataxia without spasticity in the third, and a very mild gait ataxia in the fourth. Two of the siblings also manifest vestibular failure. The remaining eight unaffected siblings are either heterozygous for the p.Ala510Val variant, or do not carry it at all. Homozygosity mapping using a high-density SNP array across the whole genome found just 11 genes (on two regions of chromosome 3) outside the SPG7 region on chromosome 16, which were homozygously shared by the affected siblings, but not shared by the unaffected siblings; none of them are likely to be causative. The weight of evidence is strongly in favour of the p.Ala510Val variant being a disease-causing mutation. We present additional data from the Auckland City Hospital neurogenetics clinic to show that the p.Ala510Val mutation is prevalent amongst HSP patients of UK extraction belying any suggestion that European p.Ala510Val haplotypes harbour a disease-causing mutation which the UK p.Ala510Val haplotypes do not. Taken together with previous findings of a carrier frequency of 3-4 % in the UK population (giving a homozygosity rate of 20-40/100,000), the data imply that the p.Ala510Val is the most common mutation causing neurogenetic disease in adults of UK ancestry, albeit the penetrance may be low or the disease caused may be mild.
MeSH Terms
ATPases Associated with Diverse Cellular Activities
Adult
Age of Onset
Alanine/genetics
Female
Genetic Predisposition to Disease/genetics
Genetic Testing
Genotype
Humans
Magnetic Resonance Imaging
Male
Metalloendopeptidases/genetics
Middle Aged
Mutation/genetics
Pedigree
Spastic Paraplegia, Hereditary/genetics,physiopathology
United Kingdom
Valine/genetics
Vestibular Diseases/genetics
Whites/genetics
Chemicals
Metalloendopeptidases
SPG7 protein, human
ATPases Associated with Diverse Cellular Activities
Valine
Alanine
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Roxburgh Richard H
Neurology Department, Auckland City Hospital, Private Bag 92024, Auckland 1142, New Zealand.
[email protected]
Marquis-Nicholson Renate
Ashton Fern
George Alice M
Lea Rod A
Eccles David
Mossman Stuart
Bird Thomas
van Gassen Koen L
Kamsteeg Erik-Jan
Love Donald R
References (16)
16 references, click to expand
-
Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease.
Cell. 1998 Jun 12;93(6):973-83
PMID: 9635427
-
Paraplegin gene analysis in hereditary spastic paraparesis (HSP) pedigrees in northeast England.
Neurology. 2001 Feb 27;56(4):467-71
PMID: 11222789
-
Prevalence of multiple sclerosis in Rochdale.
J Neurol Neurosurg Psychiatry. 1996 Oct;61(4):415-7
PMID: 8890784
-
Amplicon-based high-throughput pooled sequencing identifies mutations in CYP7B1 and SPG7 in sporadic spastic paraplegia patients.
Clin Genet. 2011 Aug;80(2):148-60
PMID: 21623769
-
Functional evaluation of paraplegin mutations by a yeast complementation assay.
Hum Mutat. 2010 May;31(5):617-21
PMID: 20186691
-
A haplotype map of the human genome.
Nature. 2005 Oct 27;437(7063):1299-320
PMID: 16255080
-
A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia.
Brain. 2004 May;127(Pt 5):973-80
PMID: 14985266
-
Cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS): a review of the clinical features and video-oculographic diagnosis.
Ann N Y Acad Sci. 2011 Sep;1233:139-47
PMID: 21950986
-
SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V.
Clin Genet. 2013 Mar;83(3):257-62
PMID: 22571692
-
A clinical, genetic, and biochemical characterization of SPG7 mutations in a large cohort of patients with hereditary spastic paraplegia.
Hum Mutat. 2008 Apr;29(4):522-31
PMID: 18200586
-
Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus.
J Neurol. 2011 Jul;258(7):1207-22
PMID: 21461686
-
Visual vestibular interaction in the dynamic visual acuity test during voluntary head rotation.
Aviat Space Environ Med. 1997 Feb;68(2):111-7
PMID: 9125086
-
Head impulse test in unilateral vestibular loss: vestibulo-ocular reflex and catch-up saccades.
Neurology. 2008 Feb 5;70(6):454-63
PMID: 18250290
-
Mutation analysis of the paraplegin gene (SPG7) in patients with hereditary spastic paraplegia.
Neurology. 2006 Mar 14;66(5):654-9
PMID: 16534102
-
Haploview: analysis and visualization of LD and haplotype maps.
Bioinformatics. 2005 Jan 15;21(2):263-5
PMID: 15297300
-
Paraplegin mutations in sporadic adult-onset upper motor neuron syndromes.
Neurology. 2008 Nov 4;71(19):1500-5
PMID: 18799786